Article

In The Literature: MicroRNA Biomarkers Could Predict Chemotherapy Response in Lung Cancer

MicroRNAs have the potential to be predictive biomarkers that can predict survival as well as response to chemotherapy, as this study discovered.

Tumor samples from recurrent lung adenocarcinoma patients treated with platinum-based doublet chemotherapy were analyzed for microRNA expression. The analysis identified a signature: miR1290, miR196b, and miR135a*. These 3 microRNAs could predict chemotherapy response, not progression-free survival or overall survival, in patients with recurrent lung cancer.

Link to the abstract in Clinical Cancer Research: http://bit.ly/1m5Ed8v

Related Videos
Nini Wu, MD, Navista
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Lalan Wilfong, MD
Katherine Baker, MD, MMHC
Nini Wu, MD, MBA
Andrew Chapman, DO
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Related Content
Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
May 18th 2025

Novel, Non-Invasive Skin Cancer Detection Method Shows Promise

Jared Kaltwasser
The tool could make it easier for clinicians to rule out melanoma without the need for excision.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
May 14th 2025

Flow Cytometry Can Reliably Identify CTC in Melanoma

AJMC Contributor
The study, which used flow cytometry rather than molecular biology to identify circulating tumor cells (CTCs), found a significant positive correlation between the number of CTCs and the stage of disease.
Managed Care Cast logo
April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
May 14th 2025

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

Rose McNulty
Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.
Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com
May 12th 2025

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

AJMC Contributor
Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo